Differential Diagnosis of Neuroblastoma and Burkitt's Tumour
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Retinoblastoma Tumor-Suppressor Gene, the Exception That Proves the Rule
Oncogene (2006) 25, 5233–5243 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc REVIEW The retinoblastoma tumor-suppressor gene, the exception that proves the rule DW Goodrich Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA The retinoblastoma tumor-suppressor gene (Rb1)is transmission of one mutationally inactivated Rb1 allele centrally important in cancer research. Mutational and loss of the remaining wild-type allele in somatic inactivation of Rb1 causes the pediatric cancer retino- retinal cells. Hence hereditary retinoblastoma typically blastoma, while deregulation ofthe pathway in which it has an earlier onset and a greater number of tumor foci functions is common in most types of human cancer. The than sporadic retinoblastoma where both Rb1 alleles Rb1-encoded protein (pRb) is well known as a general cell must be inactivated in somatic retinal cells. To this day, cycle regulator, and this activity is critical for pRb- Rb1 remains an exception among cancer-associated mediated tumor suppression. The main focus of this genes in that its mutation is apparently both necessary review, however, is on more recent evidence demonstrating and sufficient, or at least rate limiting, for the genesis of the existence ofadditional, cell type-specific pRb func- a human cancer. The simple genetics of retinoblastoma tions in cellular differentiation and survival. These has spawned the hope that a complete molecular additional functions are relevant to carcinogenesis sug- understanding of the Rb1-encoded protein (pRb) would gesting that the net effect of Rb1 loss on the behavior of lead to deeper insight into the processes of neoplastic resulting tumors is highly dependent on biological context. -
Central Nervous System Cancers Panel Members Can Be Found on Page 1151
1114 NCCN David Tran, MD, PhD; Nam Tran, MD, PhD; Frank D. Vrionis, MD, MPH, PhD; Patrick Y. Wen, MD; Central Nervous Nicole McMillian, MS; and Maria Ho, PhD System Cancers Overview In 2013, an estimated 23,130 people in the United Clinical Practice Guidelines in Oncology States will be diagnosed with primary malignant brain Louis Burt Nabors, MD; Mario Ammirati, MD, MBA; and other central nervous system (CNS) neoplasms.1 Philip J. Bierman, MD; Henry Brem, MD; Nicholas Butowski, MD; These tumors will be responsible for approximately Marc C. Chamberlain, MD; Lisa M. DeAngelis, MD; 14,080 deaths. The incidence of primary brain tumors Robert A. Fenstermaker, MD; Allan Friedman, MD; Mark R. Gilbert, MD; Deneen Hesser, MSHSA, RN, OCN; has been increasing over the past 30 years, especially in Matthias Holdhoff, MD, PhD; Larry Junck, MD; elderly persons.2 Metastatic disease to the CNS occurs Ronald Lawson, MD; Jay S. Loeffler, MD; Moshe H. Maor, MD; much more frequently, with an estimated incidence ap- Paul L. Moots, MD; Tara Morrison, MD; proximately 10 times that of primary brain tumors. An Maciej M. Mrugala, MD, PhD, MPH; Herbert B. Newton, MD; Jana Portnow, MD; Jeffrey J. Raizer, MD; Lawrence Recht, MD; estimated 20% to 40% of patients with systemic cancer Dennis C. Shrieve, MD, PhD; Allen K. Sills Jr, MD; will develop brain metastases.3 Abstract Please Note Primary and metastatic tumors of the central nervous system are The NCCN Clinical Practice Guidelines in Oncology a heterogeneous group of neoplasms with varied outcomes and (NCCN Guidelines®) are a statement of consensus of the management strategies. -
Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels. -
Cerebellar Neuroblastoma in 2.5 Years Old Child
Case Report Cerebellar Neuroblastoma in 2.5 Years Old Child Mohammad Pedram1, Majid Vafaie1, Kiavash Fekri1, Sabahat Haghi1, Iran Rashidi2, Chia Pirooti3 Abstract 1. Thalassemia and Neuroblastoma is the third most common malignancy of childhood, after leukemia Hemoglobinopathy Research Center, Ahvaz Jondishapur University of and brain tumors. Only 2% of all neuroblastoma occur in the brain. Primary Medical Sciences, Ahvaz, Iran cerebellar neuroblastoma is an specific subset of Primitive Neuroectodermal 2. Dept. of Pathology, Shafa Tumors (PNET). Meduloblastoma is a relatively common and well-established Hospital , Ahvaz Jondishapur entity, consisting of primitive and multipotential cells that may exhibit some University of Medical Sciences, evidence of neuroblastic or gliad differentiation. But cerebellar neuroblastoma Ahvaz, Iran with ultrastractural evidence of significant neuroblastic differentiation is 3. Dept. of Neurosurgery, Golestan extremely rare. We report a rare case of neuroblastoma in the cerebellum. A Hospital, Ahvaz Jondishapur 2.5-year-old Iranian boy presented with vomiting and nausea in the morning and University of Medical Sciences, ataxia. CT scan showed a tumor mass in the cerebellum and the report of Ahvaz, Iran radiologist was medulloblastoma. Light microscopic assay showed a small cell Corresponding Author: neoplasm with lobules of densely packed cells (lobulated pattern) and better Mohammad Pedram, MD; differentiated cells. Neuron-Specific Enolase was positive. Pathologic diagnosis Professor of Pediatrics Hematology- confirmed the existence of cerebellar neuroblastoma. Chemotherapy followed Oncology surgical removal. No relapse occurred 12 months after surgery. Tel: (+98) 611 374 32 85 Email: Keywords: Neuroblastoma; Cerebellum; Chemotherapy [email protected] Please cite this article as: Pedram M, Vafaie M, Fekri K, Haghi S, Rashidi I, Pirooti Ch. -
Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: an Overview Comparing Pediatric and Adult Populations
cancers Review Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations 1, 2, 2 3 Aline Rangel-Pozzo y, Luiza Sisdelli y, Maria Isabel V. Cordioli , Fernanda Vaisman , Paola Caria 4,*, Sabine Mai 1,* and Janete M. Cerutti 2 1 Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [email protected] 2 Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo/EPM, São Paulo, SP 04039-032, Brazil; [email protected] (L.S.); [email protected] (M.I.V.C.); [email protected] (J.M.C.) 3 Instituto Nacional do Câncer, Rio de Janeiro, RJ 22451-000, Brazil; [email protected] 4 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy * Correspondence: [email protected] (P.C.); [email protected] (S.M.); Tel.: +1-204-787-2135 (S.M.) These authors contributed equally to this paper. y Received: 29 September 2020; Accepted: 26 October 2020; Published: 27 October 2020 Simple Summary: Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence clinical and biological behavior in both children and adults. In this review, we focus on the comparison between pediatric and adult PTC, highlighting genetic alterations, telomere-related genomic instability and changes in nuclear organization as novel biomarkers for thyroid cancers. Abstract: Thyroid cancer is a rare malignancy in the pediatric population that is highly associated with disease aggressiveness and advanced disease stages when compared to adult population. -
Inhibitors of Mammalian Target of Rapamycin Downregulate MYCN Protein Expression and Inhibit Neuroblastoma Growth in Vitro and in Vivo
Oncogene (2008) 27, 2910–2922 & 2008 Nature Publishing Group All rights reserved 0950-9232/08 $30.00 www.nature.com/onc ORIGINAL ARTICLE Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo JI Johnsen1,6, L Segerstro¨ m1,6, A Orrego2, L Elfman1, M Henriksson3,BKa˚ gedal4, S Eksborg1, B Sveinbjo¨ rnsson1,5 and P Kogner1 1Department of Woman and Child Health, Karolinska Institutet, Childhood Cancer Research Unit, Stockholm, Sweden; 2Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; 3Department of Microbiology, Tumor and Cellbiology, Karolinska Institutet, Stockholm, Sweden; 4Division of Clinical Chemistry, Faculty of Health Sciences, Linko¨ping University, Sweden and 5Department of Cell Biology and Histology, University of Tromso¨, Tromso¨, Norway Mammalian target of rapamycin (mTOR) has been shown the most common and deadly solid tumor of childhood to play an important function in cell proliferation, (Brodeur, 2003). Amplification of the MYCN oncogene metabolism and tumorigenesis, and proteins that regulate is associated with rapid tumor progression and fre- signaling through mTOR are frequently altered in human quently detected in advanced-stage neuroblastoma, but cancers. In this study we investigated the phosphorylation is also a major negative prognostic factor in localized status of key proteins in the PI3K/AKT/mTOR pathway tumors (Schwab et al., 2003). Advanced-stage tumors and the effects of the mTOR inhibitors rapamycin and and those with MYCN amplification show typically CCI-779 on neuroblastoma tumorigenesis. Significant emergence of treatment resistance, and alternative expression of activated AKT and mTOR were detected treatment strategies for these patients are therefore in all primary neuroblastoma tissue samples investigated, urgently needed. -
1P36 Tumor Suppression—A Matter of Dosage?
Published OnlineFirst November 20, 2012; DOI: 10.1158/0008-5472.CAN-12-2230 Cancer Review Research 1p36 Tumor Suppression—A Matter of Dosage? Kai-Oliver Henrich, Manfred Schwab, and Frank Westermann Abstract A broad range of human malignancies is associated with nonrandom 1p36 deletions, suggesting the existence of tumor suppressors encoded in this region. Evidence for tumor-specific inactivation of 1p36 genes in the classic "two-hit" manner is scarce; however, many tumor suppressors do not require complete inactivation but contribute to tumorigenesis by partial impairment. We discuss recent data derived from both human tumors and functional cancer models indicating that the 1p36 genes CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a contribute to cancer development when reduced in dosage by genomic copy number loss or other mechanisms. We explore potential interactions among these candidates and propose a model where heterozygous 1p36 deletion impairs oncosuppressive pathways via simultaneous downregulation of several dosage-dependent tumor suppressor genes. Cancer Res; 72(23); 1–10. Ó2012 AACR. Introduction (Fig. 1; refs. 1, 17–29). Despite extensive 1p36 candidate gene Deletions of the distal short arm of chromosome 1 (1p) are sequence analyses, success was limited for identifying tumor- fi frequently observed in a broad range of human cancers, speci c mutations in neuroblastomas or other malignancies, including breast cancer, cervical cancer, pancreatic cancer, which led some to conclude that a deletion mapping approach pheochromocytoma, thyroid cancer, hepatocellular cancer, was unlikely to deliver tumor suppressor genes. Many tumor colorectal cancer, lung cancer, glioma, meningioma, neuro- suppressor genes, however, do not require inactivation in a blastoma, melanoma, Merkel cell carcinoma, rhabdomyosar- classic "two-hit" manner but contribute to tumor development coma, acute myeloid leukemia, chronic myeloid leukemia, and when their dosage is reduced, sometimes only subtly, by non-Hodgkin lymphoma (1, 2). -
493.Full.Pdf
THE MERICAN JOURNAL OF CANCER A Continuation of The Journal of Cancer Research VOLUMEXXXVI I DECEMBER,1939 NUMBER4 GLIOMAS IN ANIMALS A REPORTOF Two ASTROCYTOMASIN THE COMMONFOWL ERWIN JUNGHERR, D.M.V., AND ABNER WOLF, M.D. (From the Department of Animal Diseases, Storrs Agricultural Experiment Station; the Department of Neuropathology, Columbia University; the Neurological Institute of New York) In one of the first modern studies of comparative tumor pathology, Bland- Sutton (4) stated that ‘‘ no tumors are peculiar to man.” While this view was supported in general by subsequent observations, the infreqhent reports of gliomas and other tumors of the central nervous system in animals other than man seemed to be significant. This low incidence, however, is probably more apparent than real. In a recent dissertation on the subject, Grun (20) points out that post-mortem examination of the brain in animals is performed com- paratively infrequently and that possible carriers of tumors of the central nerv- ous system are often disposed of by slaughter without adequate study. Enhanced interest in the study of brain tumors in man has been reflected in the increased number of reports of cerebral neoplasms in animals, espe- cially during the past decade, but many of these cases have been so inade- quately described that even an approximate classification is difficult. There is thus a definite need for wider information on the comparative pathology of tumors of the nervous system. The present communication aims to contribute to the subject by a brief critical review of the literature on gliomas in the lower animals, and by the reports of two additional cases in the common fowl. -
Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
International Journal of Molecular Sciences Review Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies 1, 2, 2 2, Kinga B. Stopa y , Agnieszka A. Kusiak y, Mateusz D. Szopa , Pawel E. Ferdek * and Monika A. Jakubowska 1,* 1 Malopolska Centre of Biotechnology, Jagiellonian University, ul. Gronostajowa 7A, 30-387 Krakow, Poland; [email protected] 2 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Krakow, Poland; [email protected] (A.A.K.); [email protected] (M.D.S.) * Correspondence: [email protected] (P.E.F.); [email protected] (M.A.J.) These authors contributed equally to this work. y Received: 9 April 2020; Accepted: 29 April 2020; Published: 1 May 2020 Abstract: Pancreatic ductal adenocarcinoma (PDAC) causes annually well over 400,000 deaths world-wide and remains one of the major unresolved health problems. This exocrine pancreatic cancer originates from the mutated epithelial cells: acinar and ductal cells. However, the epithelia-derived cancer component forms only a relatively small fraction of the tumor mass. The majority of the tumor consists of acellular fibrous stroma and diverse populations of the non-neoplastic cancer-associated cells. Importantly, the tumor microenvironment is maintained by dynamic cell-cell and cell-matrix interactions. In this article, we aim to review the most common drivers of PDAC. Then we summarize the current knowledge on PDAC microenvironment, particularly in relation to pancreatic cancer therapy. The focus is placed on the acellular stroma as well as cell populations that inhabit the matrix. -
Retinoblastoma
A Parent’s Guide to Understanding Retinoblastoma 1 Acknowledgements This book is dedicated to the thousands of children and families who have lived through retinoblastoma and to the physicians, nurses, technical staf and members of our retinoblastoma team in New York. David Abramson, MD We thank the individuals and foundations Chief Ophthalmic Oncology who have generously supported our research, teaching, and other eforts over the years. We especially thank: Charles A. Frueauf Foundation Rose M. Badgeley Charitable Trust Leo Rosner Foundation, Inc. Invest 4 Children Perry’s Promise Fund Jasmine H. Francis, MD The 7th District Association of Masonic Lodges Ophthalmic Oncologist in Manhattan Table of Contents What is Retinoblastoma? ..........................................................................................................3 Structure & Function of the Eye ...........................................................................................4 Signs & Symptoms .......................................................................................................................6 Genetics ..........................................................................................................................................7 Genetic Testing .............................................................................................................................8 Examination Schedule for Patients with a Family History ........................................ 10 Retinoblastoma Facts ................................................................................................................11 -
Risk Factors for Neuroblastoma
cancer.org | 1.800.227.2345 Neuroblastoma Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that increases your chances of getting a disease such as cancer. Learn more about the risk factors for neuroblastoma. ● Risk Factors for Neuroblastoma ● What Causes Neuroblastoma? Prevention The risk of many adult cancers can be reduced with certain lifestyle changes , but at this time there are no known ways to prevent most cancers in children. The only known risk factors for neuroblastoma cannot be changed. There are no known lifestyle-related or environmental causes of neuroblastoma at this time. ● Can Neuroblastoma Be Prevented? Risk Factors for Neuroblastoma A risk factor is anything that increases the chances of getting a disease such as cancer. Different types of cancer have different risk factors. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Lifestyle-related risk factors such as body weight, physical activity, diet, and the use of tobacco and alcohol play a major role in many adult cancers. But these factors usually take many years to influence cancer risk, and they are not thought to play much of a role in childhood cancers, including neuroblastomas. No environmental factors (such as being exposed to chemicals or radiation during the mother’s pregnancy or in early childhood) are known to increase the chance of getting neuroblastoma. Age Neuroblastoma is most common in infants and very young children. It is very rare in people over the age of 10 years. Heredity Most neuroblastomas do not seem to run in families. But in about 1% to 2% of cases, children with neuroblastoma have a family history of it. -
Pancreatic Neuroendocrine Tumours in Patients with Von Hippel-Lindau Disease
Review Endokrynologia Polska DOI: 10.5603/EP.a2020.0027 Volume/Tom 71; Number/Numer 3/2020 ISSN 0423–104X Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease Agnieszka Zwolak1, 2, Joanna Świrska1, 2, Ewa Tywanek1, 2, Marta Dudzińska1, Jerzy S. Tarach2, Beata Matyjaszek-Matuszek2 1Chair of Internal Medicine and Department of Internal Nursing, Medical University in Lublin, Poland 2Department of Endocrinology, Medical University in Lublin, Poland Abstract Von Hippel-Lindau disease is a highly penetrant autosomal genetic disorder caused by a germline mutation in the tumour suppressor gene, manifesting with the formation of various tumours, including neuroendocrine tumours of the pancreas. The incidence of the latter is not very high, varying from 5% to 18%. To compare, haemangioblastomas and clear cell renal carcinoma are present in 70% of von Hippel-Lindau patients and are considered the main prognostic factors, with renal cancer being the most common cause of death. However, pancreatic neuroendocrine tumours should not be neglected, considering their malignant potential (different to sporadic cases), natural history, and treatment protocol. This paper aims to review the literature on the epidemiology, natural history, treatment, and surveillance of individuals affected by pancreatic neuroendocrine tumours in von Hippel-Lindau disease. (Endokrynol Pol 2020; 71 (3): 256–259) Key words: pancreatic neuroendocrine tumours; von Hippel-Lindau disease REVIEW Introduction 52 VHL patients evaluated by Hough, there were six people (12%) in whom pancreatic involvement was the Von Hippel-Lindau disease (VHL) is a highly penetrant only abdominal manifestation of the disease [9]. Fur- autosomal genetic disorder caused by a germline muta- thermore, in the study by Hammel, VHL disease was tion in the VHL tumour suppressor gene located on the diagnosed accidently in 6% of patients during imaging short arm of chromosome 3.